– USA, MA – Checkmate Pharmaceuticals, Inc. (Nasdaq: CMPI), a clinical-stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced the appointment of Alan Bash to its Board of Directors as President and CEO, effective March 1, 2022, to succeed Alan Fuhrman, who has served as interim President and CEO since October 2021 and will continue to serve on the Board of Directors.
“I am very pleased to welcome Alan Bash as President and CEO. With over two decades of leadership experience at Bristol Myers Squibb, Mr. Bash has extensive expertise translating innovative science into meaningful advances for patients, notably driving the successful launch and commercialization of Opdivo and Yervoy,” said Board chairman, Mike Powell. “Under Alan’s leadership, Checkmate will continue developing novel treatments for patients with difficult-to-treat cancers. The Company’s lead program vidutolimod, continues to progress in multiple clinical studies and towards registration in refractory melanoma.”
His appointment follows the recent additions of Dr. Jon Wigginton and Dr. Joy Yan to the Board of Directors.
About Alan Bash
Mr. Bash will join Checkmate from Bristol Myers Squibb, where he currently serves as SVP, Commercial Model Innovation, and before that, SVP, Commercial for Immunology and Fibrosis, partnering with Research & Development to advance early and late-stage assets in the integrated BMS and Celgene portfolios. He has deep expertise in immuno-oncology, having led the U.S. launch of the PD-1 checkpoint inhibitor, Opdivo; serving as franchise lead for metastatic melanoma, and leading the launch of the first FDA-approved checkpoint combination. He also served as Worldwide VP for BMS’s lung cancer franchise and led the product team for targeted treatment for head and neck cancer and colorectal cancer.
“I am honored to be joining an experienced management team, an accomplished Board, and a Company built on the potential to improve the lives of those living with cancer,” said Mr. Bash. “Vidutolimod combines a powerful, unique immune activator, CpG-A DNA, with an innovative delivery platform, that has demonstrated potential best-in-class efficacy in certain patients whose tumors were non-responsive to approved immunotherapies.”
He earned his BA from Georgetown University and his MBA from Columbia Business School.
About Checkmate
Checkmate Pharmaceuticals is a clinical-stage biotechnology company focused on developing its proprietary technology to harness the power of the immune system to combat cancer. Checkmate Pharmaceuticals’ product candidate, vidutolimod, is an advanced generation Toll-like receptor 9 agonist, delivered as a biologic virus-like particle utilizing a CpG-A oligodeoxynucleotide as a key component, designed to trigger the body’s innate immune system to attack tumors in combination with other therapies.
For more information: https://checkmatepharma.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.